All News

Rivaroxaban and aspirin results in a 33% reduction in major adverse limb events both early and late following lower extremity revascularization.

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo meets prespecified criteria for duration of response and objective response rate.

In the third part of the series, we further explore the factors that contribute to overall happiness in a position.

The changes, which will be effective January 1, 2024, include pre-filled pens, vials of basal, vials of bolus, and pre-mix insulins.

When choosing an appropriate system, pharmacists must consider all data, as not all CSTDs are equally effective.

Study includes healthy individuals and those who had progressive multiple sclerosis with the nasally administered treatment.

The fourth dose of the bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received 3 doses of the original vaccine.

Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.

Perceived stress and cognitive performance are independently associated. Stress can also increase the risk of worsening cognition.

Furosemide exhibits diuretic action by inhibiting sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle.

Few Americans' diets meet the FDA's dietary guidelines; minerals and vitamins can pick up the slack to contribute to digestive health.

Pharmacists should continue to seek out opportunities to be involved in family medicine and chronic disease state management to make meaningful impacts on care.

Find nontraditional financing streams, identify optimal learning materials to dive into this growing space.

Pharmacists are the best resource at cancer center practices to ensure patients with cancer do not need to make the choice to stop or delay therapy due to financial reasons.

Patients with diabetes who followed a plant-based, low-carbohydrate diet and participated in healthy lifestyle habits experienced the most health benefits.

Eli Lilly treatment targets soluble amyloid beta and did not clear plaque or halt accumulation of amyloid in individuals treated with the drug in the A4 study.

Hannah Nivens, CPhT, a pharmacy distribution specialist at Novant Health Pharmacy Administration, discusses pharmacy distribution for pharmacy technicians.

Molecular complexes can serve as a D-glucose chemical sensor with chiral selectivity and sensitivity to improve diabetes testing.

Trofinetide is the first and only drug approved for the treatment of Rett syndrome.

Emily Graham, PharmD, MS, BCOP, an Oncology Clinical Pharmacy Specialist at Allegheny Health Network in Pittsburg, Pennsylvania, discusses the potential outcomes of mirvetuximab for patients with platinum-resistant ovarian cancer.

These infections can include the central nervous system (CNS), circulation, invaded organs, lower airway, and the middle ear, with outcomes that can be permanent.

The application is based on phase 3 results from the DINAMO trial showing that Jardiance tablets significantly reduced A1C levels vs a placebo in participants aged 10 to 17 years.

Median overall survival was also 2 months less for patients with extensive-stage small cell lung cancer who were ineligible for clinical trials.

Frequent aspirin use associated with a 13% lower risk of nonmucinous ovarian cancer, which was consistent with findings from previous studies.

Shane Desselle, RPh, PhD, FAPhA, associate dean for Research and Professional Affairs at the Touro University California College of Pharmacy, discusses what the Granada Statements are and why they are important for student pharmacists.

The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.

In part 2 of this panel discussion, experts discuss how they define traditional versus nontraditional oncology pharmacy roles and where roles within industry fit in.

On April 2, 2023, the FDA will announce the approval status of Roche’s supplemental Biologics License Application for polatuzumab in the treatment of diffuse large B-cell lymphoma.